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The hyperglycaemic state seen in diabetes mellitus is 
associated with the development of diabetes-specific 
microvascular complications and accelerated macro-
vascular disease. Evidence implicates the formation 
and subsequent effects of advanced glycation end-
products (AGEs) as a contributing cause. AGEs exert 
their effects through interaction with the Receptor for 
AGE (RAGE) which upregulates expression of the 
receptor and induces a cascade of cytotoxic pathways. 
Accumulation of AGE/RAGE can be seen at sites of 
vascular disease in both animal models of diabetes 
and human diabetic subjects. Blockade of RAGE in 
animal models of diabetes suppresses development of 
dysfunction in the vasculature and atherosclerosis 
development. Genetic studies of RAGE reveal that a 
number of allelic variants of RAGE occur in key pro-
tein and regulatory domains. A Gly to Ser change at 
position 82 and two 5′  flanking polymorphisms at  
position –374 and –429 lead to altered function and 
expression of RAGE which may impact on diabetic 
vascular disease development. Therapy aimed to 
block RAGE upregulation may prove to be useful in 
treating individuals with diabetic vascular disease. 
 
DIABETES mellitus is the most prevalent metabolic syn-
drome world-wide with an incidence varying between 1 
to 8% (refs 1, 2). Diabetes is characterized by hypergly-
caemia resulting in various short-term metabolic changes 
in lipid and protein metabolism and long-term irreversi-
ble vascular changes. These include diabetes-specific 
complications of the micro-vasculature system (retinopa-
thy, nephropathy and neuropathy) and complications of 
the macro-vasculature (atherosclerosis leading to heart 
disease, stroke and peripheral vascular disease) which are 
present in the non-diabetic population, but have a two to 
five-fold increase in diabetic subjects3. The incidence of 
diabetes is predicted to double over the next decade, pos-
sibly due to changes in lifestyles and the associated obe-
sity in developed countries4. These predictions are likely 
to have long-term consequences on the health care deliv-
ery system, as the number of patients with type 2 diabetes 
is expected to continue to rise. 
 Two landmark studies, the Diabetes Control and Com-
plications Trial (DCCT) and United Kingdom Prospec-
tive Diabetes Study (UKPDS) have shown that strict 
control of hyperglycemia reduces the incidence of dia-
betic micro-vascular disease5,6. However, these studies 
did not show a similar consistent effect of glycemia on 
the impact of macrovascular disease, which suggests that 
factors beyond the direct effects of high glucose imparted 
a long-term, maladaptive ‘memory’ in cells of the blood 
vessel wall. Consequences of this phenomenon include 
accelerated atherosclerosis and cerebro-/cardiovascular 
disease, as well as enhanced neointimal expansion upon 
arterial injury, such as that induced by angioplasty. The 
identification of genes and cellular mechanisms respon-
sible for these effects is of obvious significance and has 
therefore been the focus of many studies. 
 Various metabolic theories have been proposed to  
explain this relationship which include increased flux 
through the aldose reductase pathway, the sustained acti-
vation of protein kinase C (PKC) by increased levels of 
diacylglycerol (DAG), and the non-enzymatic glycation 
of macromolecules. The most compelling of these theo-
ries is the formation of advanced glycation end products 
(AGEs), evidenced by the findings of the UKPDS which 
indicate for every 1% increase in glycated haemoglobin 
levels, a 37% increase in microvascular disease was 
seen6. The formation of AGEs occurs from the reactive 
nature of reducing sugars (i.e. glucose) to undergo non-
enzymatic rearrangements with amino groups of proteins 
and possibly DNA to form irreversible cross-links.  
Although this mechanism has only been accepted as a 
plausible pathway implicated in the pathogenesis of vas-
cular disease in the last decade, the underlying biochemi-
cal reaction process has been known for almost a century. 
 The in vivo formation of non-enzymatic glycated com-
pounds was first detected in 1969 from studies on chro-
motagenic mobilities of fast moving, minor hemoglobins 
from diabetic patients, in particular HbA1C, now rou-
tinely used as a clinical tool in the management of gly-
caemic control in diabetic patients7. Its relevance was 
established in diabetic rats where hyperglycaemia was 
seen to affect the colour and protein structure changes in 
the lens8. From this hyperglycaemic-induced colour 
change, Cerami et al.8 postulated the relevance of ‘non-
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enzymatic glycosylation’ in the sequelae of diabetes, fur-
ther evidenced by Podger et al.9 who observed that cata-
racts with this characteristic colour change occur at an 
average of 10–15 years earlier in diabetic subjects. 
 The glycation process, otherwise known as the Mail-
lard reaction, is divided into three key stages: the early 
reactions resulting in the formation of a Schiff base and 
Amadori products, the rearrangements of these chemical 
groups and the final reactions forming the classical Mail-
lard browning products or now known as AGEs10. AGEs 
were originally shown to form over a period of weeks to 
months on long-lived cellular proteins, however, evi-
dence suggests that glucose is not the only precursor of 
AGE, as other aldoses react more rapidly with proteins 
than glucose, including metabolites from the glycolysis 
and the polyol pathway11. This could, therefore, suggest a 
possible role for aldose reductase and this pathway in the 
formation of AGE. Recent findings indicate that AGE 
can also originate from the α-oxoaldehydes, methylgly-
oxal, glyoxal and the highly reactive 3-deoxyglucosone, 
also formed from degradation of an Amadori product12. 
 A number of AGEs have been isolated or synthesized 
de novo, the two most studied being N-(carboxy- 
methyl)lysine (CML)13 and pentosidine14. Others include 
2-2(furoyl)-4(5)-(2-furanyl)-1H-imidazole (FFI)15, pyr-
raline16, 1-alkyl-2-formyl-3,4-diglucsyl-pyrrole (AFGP)17 
and more recently 3-deoxyglucosone derived AGEs  
including deoxyglucasone-lysine dimer and methyl gly-
oxal lysine dimer10. Both CML and pentosidine have 
been found to accumulate in the skin and lens with age-
ing and at an accelerated rate in diabetes18,19. In addition, 
studies on pentosidine identified increased levels in the 
skin of diabetics, associated with the severity of the com-
plications found in these patients20 and increased levels 
in patients with microalbuminuria21. 
 The role of AGE in vascular disease was first identi-
fied by their ability to cross-link proteins of the vascular 
wall leading to the thickening of vessels and leakage 
from the vasculature22. Further evidence to support this 
was seen in animal models of diabetes which demon-
strated that the inhibitor of AGE formation, aminogua-
nidine, blocked the cellular mechanisms underlying both 
micro and macrovascular disease22. AGE have been 
shown to produce a variety of toxic effects by a number 
of mechanisms. Firstly, the formation of AGE occurs on 
the extracellular matrix leading to the trapping of pro-
teins and eventual narrowing of the lumen. Secondly, 
AGE formation occurs intracellularly through rapid in-
termediates of glucose metabolism, altering protein struc-
ture and function. Thirdly, AGE interact with AGE 
binding receptors which remove and degrade AGEs and 
activate proinflammatory and prothrombotic pathways. A 
variety of candidates receptors have been identified 
which include the AGE–receptor complex (AGE-R1-
3)23,24, macrophage scavenger receptors (type I and 
II)25,26, the receptor for advanced glycation end products 
(RAGE)27, CD-36 (ref. 28) and most recently LOX-129. 
To-date the majority of studies support RAGE as a cen-
tral role in the biology and pathogenesis of AGEs. 
 RAGE was initially identified by its ability to bind and 
internalize AGEs, however, subsequent studies now sug-
gest that RAGE is a signalling receptor, as ligand enga-
gement modulates cellular function to show RAGE is not 
likely to be a scavenger of AGEs30. Characterization of 
RAGE identified it as a member of the immunoglobulin 
superfamily of receptors31. RAGE is composed of three 
immunoglobulin domains, one V-type and two C-type 
domains, with a single transmembrane region and a short 
high charged cytosolic tail of 43 amino acids necessary 
for signalling32. Indeed, studies have suggested that tran-
sient transfection of (endogenous) RAGE-bearing cells 
with RAGE constructs in which solely the cytosolic  
domain was deleted revealed that upon ligand stimula-
tion, cellular signalling and altered gene expression were 
effectively suppressed33. These observations suggested 
that deletion of the RAGE cytosolic domain imparted a 
‘dominant negative’ (DN) effect. We have confirmed 
these observations in both in vitro and in vivo analyses; 
in the latter employing transgenic animals bearing  
DN-RAGE34. 
 The AGE-binding domain of RAGE was experimen-
tally determined to be within the first 30 amino acids of 
the V-domain35. Two isoforms of RAGE were originally 
detected consisting of 45 kDa and 35 kDa (ref. 27). This 
was later confirmed to occur in most cells studied, except 
for neuronal tissue where a 48 kDa and 23 kDa were iso-
lated, and suggested to arise from posttranslational proc-
essing of RAGE36. The 35 kDa isoform of RAGE was 
experimentally produced by producing a truncated ver-
sion of RAGE including the extracellular domain of 
RAGE, and designated as soluble RAGE (sRAGE)37. 
RAGE is expressed by most cell types including vascular 
endothelium and smooth muscle, monocytes, macro-
phages, glomerular epithelial cells and neuronal cells36. 
 RAGE is normally expressed at low levels in most tis-
sues except lung, however, in atherosclerotic lesions 
from diabetic subjects RAGE is highly upregulated com-
pared to healthy subjects36. This is also seen in animal 
models of diabetes which show up-regulated RAGE in 
vascular endothelium and smooth muscle36,38. The increa-
sed expression of RAGE has been demonstrated in a  
variety of other diabetic vascular disease states, including 
the vascular smooth muscle39, the glomeruli, podocytes 
and tubular epithelial of the kidney40, the endothelium in 
peripheral occlusive vascular disease41 and the fibrovas-
cular membranes of the retina42. However, RAGE expres-
sion is increased in a number of disease states, involving 
non-AGE related inflammatory diseases40. 
 AGE and RAGE were found to co-accumulate with 
diabetes in renal glomerulus, retina and aorta, and both 
AGE levels and RAGE expression was reduced by treat-
ment with aminoguanidine43. The accumulation of AGE 
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and RAGE was studied in more depth in cardiovascular 
tissue of the diabetic rat, demonstrating the increased 
accumulation of AGE with diabetes and increased  
expression of RAGE in the endothelium and vascular 
smooth muscle with duration of hyperglycaemia38. 
 Investigations into the molecular mechanism underly-
ing RAGE activation in these processes, revealed the 
induction of an oxidative process arising from the infu-
sion of AGE into rats, dependent on RAGE44. An AGE/ 
RAGE mechanism was shown to induce dysfunction in 
the endothelium resulting in hyperpermeability, reversed 
by the blockage of AGE/RAGE interaction by antibodies 
to RAGE45. At the cellular level, AGE/RAGE was found 
to induce the activation and nuclear translocation of  
Nuclear Factor-κB (NF-κB), a transcription factor  
responsible for the induction of endothelium/leukocyte 
adhesion molecules implicated in the initiation of the 
atherosclerotic lesions and other vascular disorders46. 
Expression of RAGE was found to be dependent on a 
number of key NF-κB sites47, which demonstrated a pos-
sible feedback-loop of increased expression of RAGE 
arising from AGE/RAGE interaction. 
 The involvement of NF-κB via RAGE and its role in 
the pathogenesis of vascular disease was further revealed 
by the finding of increased expression of VCAM-1 in the 
endothelium resulting from exposure to AGE48. VCAM-1 
has been shown to be expressed on the endothelium in 
atherosclerotic plaques, resulting in an increase in mono-
cyte adhesion49. Monocytes bearing RAGE at their sur-
face are recruited by a chemotaxic mechanism to sites of 
AGE accumulation50, whereupon they infiltrate to the 
subendothelium to eventually form foam cells, an early 
step in the development of atherosclerosis51. In addition 
to this, the secretion of chemoattractant molecules from 
vascular smooth muscle cells (VSMC) could be induced 
by AGE/RAGE, demonstrating a further mechanism to 
induce monocyte infiltration52. 
 This mechanism of chemotaxis could also be demon-
strated using AGEs isolated directly from diabetic pati-
ents, showing RAGE to bind true physiological AGEs48. 
For all other identified AGE-receptors, experiments have 
only been performed using in vitro-produced AGEs, 
which are proposed to be highly over-glycated in com-
parison with in vivo occurring AGEs53. This is thought to 
result in a high degree of non-specific binding to the cell 
surface, which can render the non-specific AGE-binding 
effect54. 
 The interaction of AGE with the endothelium also 
leads to the synthesis of a number of other proteins, with 
relevance to both macro and micro vascular complica-
tions. The increased expression of tissue factor (TF) by 
both endothelium55 and macrophages56 occurs via an 
AGE/RAGE mechanism, which may initiate a procoagu-
lant state, further enhanced by the AGE/RAGE induction 
of Plasminogen Activator Inhibitor-1 (PAI-1), an attenu-
ating serine protease of fibrinolysis57. Furthermore, the 
AGE/RAGE interaction induces endothelin-1 expression, 
a potent vasoconstrictor58 and consequently inhibits the 
production of prostacyclin and nitric oxide, a potentially 
contributory factor to hypertension in diabetes59. The 
inhibition of prostacyclin production has consequences  
in the initiation of retinopathy, as a RAGE-dependent 
mechanism can be shown to reduce prostacyclin prod-
uction by the endothelium60 and result in the loss of  
pericytes61, the earliest visible marker of diabetic retino-
pathy61,62. 
 These AGE/RAGE effects were demonstrated to be 
reversible at the cellular level by blocking their interac-
tion using either antibodies directed against RAGE or 
using sRAGE, suggesting a possible therapeutic value in 
vascular disease63. Previous studies had demonstrated 
dysfunction of the endothelium to occur via an AGE/ 
RAGE mechanism by infusing red blood cells (RBCs) 
from diabetic rats into normal animals. This resulted in 
increased RBC adhesion to the endothelium, the induc-
tion of oxidative stress and general dysfunction of the 
endothelium64. Renard et al.65 repeated these studies and 
injected sRAGE into the rats, which fully reversed the 
hyperpermeability resulting from the AGE-RBCs binding 
to the endothelium. The beneficial effects of sRAGE in 
the full development of vascular disease was demon-
strated in diabetes-induced streptozotocin mice, geneti-
cally engineered to rapidly develop atherosclerosis 
(apoE-null)66. Infusion of mice with sRAGE suppressed 
development of accelerated atherosclerotic lesions in a 
glycaemic and lipid-independent manner66. 
 The biology of RAGE extends beyond the scope of 
binding and mediating the effects of AGEs. The finding 
that RAGE was upregulated in non-diabetic subjects with 
vascular disease and in non-diabetic Apo-E mice suggest 
the role of other non-AGE ligand activating RAGE41. 
Studies have so far identified RAGE to bind a variety of 
ligands which include the neural development regulator, 
amphoterin67 and the protein involved in Alzheimer’s 
disease, β-amyloid68 (see Table 1). The role of the high 
 
 
Table 1. Known ligands for RAGE and their potential impact in 
  homeostasis and pathophysiological settings 
Ligands for receptor for AGE Physiologic/pathophysiologic impact 
 
Advanced glycation Diabetes, renal failure, amyloidoses, 
 endproducts  (e.g. CML-adducts) inflammation, 
  oxidant stress, aging 
 
Amyloid-β peptide and β-sheet Alzheimer’s disease, amyloidoses 
 fibrils 
 
S100/calgranulins  Development, neurite outgrowth
  inflammation, tumour biology 
 
Amphoterin  Development, neurite outgrowth 
  inflammation, tumour biology 
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expression pattern of RAGE seen in lung and in non-
hyperglycaemic disease states may be explained by the 
recent isolation of an endogenous ligand for RAGE 
termed Extracellular Newly identified RAGE-binding 
protein or EN-RAGE33. EN-RAGE, a 12 kDa protein was 
found to bind and activate RAGE on endothelial and 
monocytic cells33. By sequence homology, EN-RAGE 
was identified as S100A12, a member of the S100 family 
of EF left hand calcium-binding proteins33. Although 
these proteins consist of ≈ 19 structurally similar mem-
bers, they have a variety of distinctly different intracellu-
lar and extracellular roles69. The S100 genes are located 
in a cluster on chromsome 1q21 and also identical in 
their genomic organization, comprising of 3 exons coding 
for the 5′ untranslated region, N-terminal EF-hand, and 
carboxyl terminal EF-hand respectively69. EN-RAGE is 
expressed by granulocytes and monocytes70, its original 
proposed role to act as a proinflammatory mediator by 
recruiting monocytes71. Interaction with RAGE on 
mononuclear phagocytes, endothelial cells and lympho-
cytes results in increased expression of proinflammatory 
mediators including tumour necrosis factor-α (TNF-α), 
VCAM-1 and interleukin-1/2 (IL-1/2)33. Studies of  
EN-RAGE/RAGE in vascular disease have identified 
EN-RAGE upregulation in atherosclerotic plaques  
together with increased RAGE and AGEs72. 
 These findings suggest RAGE to be a key target for 
both drug intervention studies and as a candidate for  
genetic studies. A role for genetic susceptibility in the 
development of diabetic vascular disease is supported by 
family studies of clustering of retinopathy and nephropa-
thy. In a follow-up study to address these issues the 
DCCT investigated the type, presence and severity of 
complications in 241 first-degree relatives of the previ-
ously investigated group, with either type 1 or 2 diabe-
tes73. With nephropathy, it appeared that a familial factor 
accounted for the five-fold increase in relatives of DCCT 
subjects and with retinopathy a clustering was seen with 
severity73. These observations led to studies to investi-
gate the presence of allelic variation in the RAGE gene 
and their effects on expression and function. 
 The gene for RAGE is located on chromosome 6p21.3 
in the major histocompatibility complex (MHC)31, in 
perhaps the most gene-rich area of the genome containing 
an average of one gene per 10 kb of DNA and many 
overlapping genes74. The gene for RAGE is no exception 
to this, as the 5′ flanking region from –505 in the 5′  
direction overlaps with PBX2, a gene which has a non-
functional pseudogene copy on chromosome 3 (ref. 75). 
The RAGE gene was assessed for the presence of  
novel polymorphisms within exons and gene regulatory 
regions which might affect function and expression of 
RAGE76–79. At first the 11 exons and 3′ UTR of RAGE 
were identified and screened and a number of amino acid 
changes which included a common variant in exon 3 
(Gly82Ser) and 3 rare coding changes (Thr187Pro, 
Gly329Arg, Arg389Gln) were identified76. Additional 
studies have identified a number of other polymorphisms 
in the coding region of RAGE (summarized in Table 2). 
However, these have all proven to be either non-codon 
changes or rare amino acid changing variants78,79. 
 Further studies were performed on the common 
Gly82Ser polymorphism as it was found to occur within 
the ligand-binding domain of RAGE, making this a pote-
ntially important gene variation. The Gly82 and Ser82 
isoforms were expressed in cells and the consequences of 
the Gly82Ser on receptor function investigated. In Chi-
nese Hamster Ovary cells (CHOs) and macrophages iso-
lated from human subjects, the Ser82 isoform displayed a 
higher affinity for the EN-RAGE ligand, and under 
stimulation with EN-RAGE led to the increased activa-
tion of the proinflammatory proteins, TNF-α, IL-6 and 
matrix metalloproteinase (MMP)80. These findings sug-
gest the possibility that the Ser82 allele may play an im-
portant role in the inflammatory component of vascular 
disease. Indeed, a number of studies have been performed 
to assess the prevalence of the Gly82Ser polymorphism 
in vascular disease of both diabetics and non-diabetics. 
Initial studies in diabetic subjects identified no differ-
ences in genotype or allele frequencies between subjects 
with or without (5% allele frequency for Ser82) macro-
vascular disease76. This result has been seen in other 
studies, in diabetics with macrovascular81 and microvas-
cular79,82,83 disease, but all of these studies have been 
limited in the size of the populations and the low 
frequency of the Ser82 allele. However, the functional 
data seen in vitro with the Gly82Ser polymorphism, sup-
ports a role for the Ser82 allele in heightening the in-
flammatory responses in vascular disease. This view may 
be supported by the identification of increased Ser82 dis-
tribution in diabetic subjects with microvascular dermato-
ses78, psoriasis vulgaris84 and in subjects with rheumatoid 
arthritis80. Both this result and the lack of association of 
Gly82Ser with vascular disease in diabetes need to be  
established in larger patient groups. The fact that polymor-
phisms of the RAGE coding region have been either very 
rare coding changes or the infrequent Gly82Ser polymor-
phism suggests the role for other regions of the RAGE 
gene affecting outcome of the polygenic nature of mi-
crovascular and macrovascular disease. Studies to address 
these issues investigated other key regions of RAGE, spe-
cifically the transcriptional regulatory regions of RAGE 
potentially affecting RAGE expression77,79. 
 Characterization of the RAGE 5′ regulatory region 
identified major sites of positive and negative regulation 
within the –1700 to +1 5′ flanking region of RAGE using 
deletion reporter gene constructs47,85. Using DNase I 
footprinting and mutagenesis, a number of NF-κB sites 
were identified to exist in the –1543 to –738 and –738 to 
–587 regions47, confirmed using ECV304 and human 
microvascular endothelial cells (HMVECs) stimulated 
with AGE and TNF-α85. Subsequently, a number of
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Table 2. Polymorphisms of the RAGE gene 
 Region Allele 
RAGE polymorphism detected frequencies Disease association studies Functional implications References 
 
–1420 (GTT)n 5′ Flanking N/A   77 
–1393 G/T 5′ Flanking N/A   77 
–1390 G/T 5′ Flanking N/A   77 
–1202 G/A 5′ Flanking N/A   77 
–405 to –345 deletion 5′ Flanking > 99% Ins,  Increased expression 77 
  < 1% Del  in reporter gene studies 
    Increased expression in 
    reporter gene studies 
–429 T/C 5′ Flanking 83% –429T, No associations with ischaemic heart Increased expression in 77, 86 
  17% –429C disease in both diabetic and non- reporter gene studies 
   diabetic individuals. Association with 
   retinopathy in diabetic individuals 
   (24% –429C, P = 0.012) 
–374 T/A 5′ Flanking 81% –374T, No associations with ischaemic heart Increased expression in  77, 79, 86, 
  19% –374A disease in both diabetic and non- reporter gene studies.  87 
   diabetic individuals. No association Altered binding of nuclear 
   with retinopathy in diabetic individuals. proteins 
   Increased frequency in non-small cell 
   lung cancer (39% –374A, P < 0.05) 
Ala2Ala (GCT/GCA) Exon 1 86% T, 14% A   76 
67 C/G Intron 1 83% C, 17% G   76 
Lys37Ser Exon 2 > 99% Lys37,   78 
  < 1% Ser37 
Arg77Cys Exon 3 > 99% Arg77,   78 
  < 1% Cys77 
Gly82Ser Exon 3 95% Gly82, No association with macrovascular Increased ligand affinity 76, 78–82 
  5% Ser82 disease in diabetic and non-diabetic and cytokine activation  84 
   subjects. No association with diabetic with Ser82 allele in 
   microvascular disease. Increased macrophages 
   frequency of Ser82 in diabetic skin 
   disorders 
Val89Val (GTG/GTC) Exon 3 95% G, 5% C   78 
Gly90Gly (GCT/GCA) Exon 3 95% T, 5% A   76 
718 G/T Intron 3 92% 718 G,   78 
  8% 718 T 
Thr187Pro Exon 6 > 99% Thr187,   76 
  < 1% Pro187 
1704 G/T Intron 7 95% 1704 G, No association with diabetic  78, 88 
  5% 1704 T retinopathy. Association with anti- 
   oxidant status in type 2 diabetic subjects 
A insertion 1727 Intron 7 N/A   78 
His305Gln Exon 8 > 99% His305,   78 
  < 1% Gln305 
Ser307Cys Exon 8 > 99% Ser307,   78 
  1% Cys307 
Gly329Arg Exon 8 > 99% Gly329,   76 
  < 1% Arg329 
2117 A/G Intron 8 N/A   78 
2184 A/G Intron 8 84% 2184 A, No association with diabetic  78, 88–89 
  16% 2184 G retinopathy. Association with 
   antioxidant status in type 2 diabetic 
   subjects. Association of the 2184G 
   allele and plaque psoriasis 
2224 A/G Intron 8 N/A   78 
2245 G/A Intron 8 92% 2245 G, No association with diabetic retinopathy  78 
  8% 2245 T 
2249 A/G Intron 8 N/A   78 
2741 G/A Intron 9 N/A   78 
Leu363Leu (CTG/TTG) Exon 10 99% C, 1% T   76 
Arg389Gln Exon 10 > 99% Arg389,   76 
  < 1% Gln389 
CA deletion 3089 3′ UTR < 1% CA deleted   78 
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polymorphisms within the RAGE 5′ flanking region were 
identified (see Table 2) which included two common sin-
gle nucleotide polymorphisms (–374 T/A and –429 T/C) 
and a 63 bp deletion spanning from –407 to –345, all 
within a region of negative gene regulation77. Functional 
analysis of these polymorphisms by reporter gene assays 
in HepG2 cells gave a 2 (–429C), 3 (–374A) and 4 (63 bp 
deletion) fold increase in chloroamphenicol acetyl trans-
ferase (CAT) expression relative to the wild type con-
struct77. These were studied further by investigating the 
influence of –429 T/C and –374 T/A on U937 and HepG2 
transcription factor binding using electrophoretic mobil-
ity shift assays (EMSAs). The –374A allele caused a 
complete loss of a DNA : protein complex from both cell 
lines77. Together with the reporter gene assays this sug-
gests that this polymorphism affected a repressor binding 
to RAGE leading to up-regulation. The prevalence of 
these polymorphisms in diabetic subjects revealed no 
difference in genotype or allele frequency with either 
polymorphism in subjects with (–429T 81%, –429C 19%; 
–374T 83%, –374A 17%) or without macrovascular dis-
ease (–429T 83%, –429C 17%; –374T 81%, –374A 
19%)86. There was, however, a significant association 
seen between the –429 T/C polymorphism and retinopa-
thy77. Diabetic subjects with retinopathy were found to 
have a statistically higher prevalence of the C allele 
23.6% vs 14.9%, with vs without retinopathy)77. Other 
investigators additionally identified a C to A polymor-
phism in the RAGE 5′ flanking region at –1152 (–1139 
from actual +1 site) which was found to associate with 
nephropathy in type 1 diabetic subjects79. However, this 
was later shown to not be a polymorphism, but to be in 
fact a gene : pseudogene difference between the 3′UTR 
of PBX2/5′ flanking region of RAGE on chromosome 6, 
and the PBX2 pseudogene on chromosome 3 (ref. 75). 
Again, larger study numbers are required to verify the 
results seen with the –374 T/A and –429 T/C polymor-
phisms and to establish whether these gene variants have 
a causative role in the pathogenesis of vascular disease. 
 In conclusion, it is highly likely that glycation and the 
ultimate formation of AGEs are central to the pathogene-
sis of diabetic vascular disease. From in vitro and in vivo 
studies, the interaction with their receptor, RAGE pre-
sents a novel target for drug intervention to reduce and 
prevent the development of the debilitating side effects of 
hyperglycaemia. Taken together with genetic susceptibil-
ity data from RAGE allelic variants which may influence 
the disease progression further, it may be possible to tai-
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